New anticoagulant agents and the future of cardiology;Los nuevos anticoagulantes y el futuro de la cardiología

Revista Espanola de Cardiologia

Volumn 63, Issue 11, 2010, Pages 1223-1229

  Andreotti, Felicita ^a   Pafundi, Teodosio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

CARDIOLOGY; REVIEW; ACUTE CORONARY SYNDROME; EDITORIAL; FORECASTING; HEART ATRIUM FIBRILLATION; HUMAN; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOLOGY; FORECASTING; HUMANS;

EID: 79751476854     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(10)70290-6     Document Type: Editorial

References (14)

1. J. Hirsh, G. Guyatt, G.W. Albers, R. Harrington, and H.J. Schunemann Antithrombotic and thrombolytic therapy 8th ed: American College of Chest Physicians' Guidelines. Executive Summary Chest 133 2008 S71 S105
2. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, and C. Held Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
3. J.I. Weitz, and S.M. Bates (Pubitemid 41716571)
4. J.L. Mega, E. Braunwald, S. Mohanavelu, P. Burton, R. Poulter, and F. Misselwitz Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial Lancet 374 2009 29 38
5. APPRAISE Steering Committee and Investigators Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome. Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial Circulation 119 2009 2877 2885
6. M. Cohen, D.L. Bhatt, J.H. Alexander, G. Montalescot, C. Bode, and T. Henry Randomised, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention. The SEPIA-PCI trial Circulation 115 2007 2642 2651 (Pubitemid 46791363)
7. M.S. Sabatine, E.M. Antman, P. Widimsky, I.O. Ebrahim, R.G. Kiss, and A. Saaiman Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial Lancet 374 2009 787 795
8. M.D. Ezekowitz, P.A. Reilly, G. Nehmiz, T.A. Simmers, R. Nagarakanti, and K. Parcham-Azad Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study) Am J Cardiol 100 2007 1419 1426 (Pubitemid 47576022)
9. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
10. D.J. Ellis, M.H. Usman, P.G. Milner, D.M. Canafax, and M.D. Ezekowitz The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation Circulation 120 2009 1029 1035
11. J.P. Piccini, R.D. Lopes, and K.W. Mahaffey Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation Curr Opin Cardiol 25 2010 312 320
12. ROCKET AF Study Investigators Rivaroxaban-Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study Am Heart J 159 2010 340 347
13. R.D. Lopes, J.H. Alexander, S.M. Al-Khatib, J. Ansell, R. Diaz, and J.D. Easton Apixaban for Reduction In Stroke and Other ThromboemboLic Events in atrial fibrillation (ARISTOTLE) trial: design and rationale Am Heart J 159 2010 331 339
14. J.W. Eikelboom, M. O'Donnell, S. Yusuf, R. Diaz, G. Flaker, and R. Hart Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment Am Heart J 159 2010 348 353